title: Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats.
abstract: Naltrexone is a μ-opioid receptor antagonist that has been extensively studied for its ability to block the rewarding effects of ethanol. Opioid receptors are widely distributed within the gastrointestinal tract (GIT). Typically, naltrexone is administered by parenteral routes in nonclinical studies. We initially tested if opioid receptors within the GIT would influence the ability of oral naltrexone to inhibit ethanol oral self-administration in rats using the co-administration of oral loperamide, a peripherally restricted opioid agonist. As expected, oral naltrexone only had modest effects on ethanol intake, and the response was not dose-dependent. However in rats, treatment with loperamide prior to the administration of naltrexone resulted in a suppression of ethanol intake which approached that observed with naltrexone given by the subcutaneous (SC) route. Importantly, administration of loperamide prior to administration of naltrexone did not alter blood concentrations of naltrexone. We then evaluated if oral loperamide would enhance effects of baclofen (a GABA(B) receptor agonist) and AM-251 (a CB-1 receptor antagonist) and found that pre-treatment with loperamide did potentiate the action of both drugs to reduce ethanol self-administration. Finally, the specific opioid receptor type involved was investigated using selective μ- and κ-receptor antagonists to determine if these would affect the ability of the AM-251 and loperamide combination to block ethanol drinking behavior. The effect of loperamide was blocked by ALKS 37, a peripherally restricted μ-receptor antagonist. These data suggest an important role for opioid receptors within the GIT in modulating central reward pathways and may provide new insights into strategies for treating reward disorders, including drug dependency.
authors: Life Sciences and Toxicology, Alkermes, Inc., Waltham, MA 02451, USA. reggie.dean@alkermes.com
authors: Reginald L
authors: RL
authors: Dean
authors: David
authors: D
authors: Eyerman
authors: Mark S
authors: MS
authors: Todtenkopf
authors: Ryan Z
authors: RZ
authors: Turncliff
authors: Jean M
authors: JM
authors: Bidlack
authors: Daniel R
authors: DR
authors: Deaver
mesh_terms: D000284:Administration, Oral; D000427:Alcohol Deterrents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000428:Alcohol Drinking / Q000517:prevention & control*; D000818:Animals; D021461:Animals, Outbred Strains; D001418:Baclofen / Q000008:administration & dosage / Q000627:therapeutic use*; D001522:Behavior, Animal / Q000187:drug effects; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D058786:GABA-B Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D008139:Loperamide / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D008297:Male; D009271:Naltrexone / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D017473:Receptors, Opioid, kappa / Q000037:antagonists & inhibitors; D017450:Receptors, Opioid, mu / Q000819:agonists* / Q000037:antagonists & inhibitors
chemical_list: D000427:Alcohol Deterrents; D058786:GABA-B Receptor Agonists; D009292:Narcotic Antagonists; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; C103505:AM 251; D009271:Naltrexone; D008139:Loperamide; D001418:Baclofen